Neuren, Metabolic report nerve regeneration data
16 February, 2006 by Ruth BeranNeuren Pharmaceuticals (ASX:NEU) and Metabolic Pharmaceuticals (ASX:MBP) have obtained promising results in an animal trial testing the ability of NNZ-4921, a neural regeneration peptide (NRP), to prevent or reverse sensory nerve damage.
Biota starts phase I trial of common cold drug
16 February, 2006 by Ruth BeranMelbourne-based Biota Holdings (ASX:BTA) has commenced a phase I clinical trial of its human rhinovirus (HRV) drug, BTA-798, for the prevention and treatment of one of the major causes of the common cold.
Peptech execs talk up pipeline
15 February, 2006 by Helen SchullerPeptech chairman Mel Bridges today told shareholders that the company's best strategy for building value was to develop its product pipeline.
Vic agbiotech centre opens its doors
15 February, 2006 by Graeme O'NeillVictoria took another step towards its biotechnology future today, with the opening of the new AUD$20 million Victorian Agribiosciences Centre at La Trobe University's R&D Park in Bundoora.
GroPep boosts half-year profit by 80 pct
15 February, 2006 by Helen SchullerAdelaide-based GroPep (ASX:GRO) has increased its profit more than 80 per cent after tax to AUD$1.55 million in the half-year to December 31 2005, compared with $850,000 in the previous corresponding period.
Cochlear boasts record half-year results
14 February, 2006 by Ruth BeranIn what CEO Chris Roberts called "an absolutely fabulous result", bionic ear specialist Cochlear (ASX:COH) has posted record revenue, cochlear implant sales, and core earnings for the half year ended December 31, 2005.
Acrux acquires rights for contraceptive spray
14 February, 2006 by Ruth BeranMelbourne-based Acrux (ASX:ACR) has signed an agreement with the New York-based Population Council to commercialise a contraceptive spray containing Nestorone, a fourth-generation progestin contraceptive which cannot be taken orally.
New research explores why there's youth in wine
14 February, 2006 by Graeme O'NeillSpanish explorer Juan Ponce de Leon might have spared himself and his men the travails of their fruitless and ultimately fatal quest for the fountain of youth in the Caribbean in 1513 by staying at home in and quaffing the genuine article from oak barrels in his wine cellar, writes Graeme O'Neill.
New agbiotech centre to open
13 February, 2006 by Ruth BeranA new AUD$20 million agricultural biotech centre will be opened by Victorian premier Steve Bracks this Wednesday.
CogState signs $400,000 functional food deal
13 February, 2006 by Ruth BeranCogState (ASX:CGS) is to provide cognition testing services to a European food products company in a contract worth more than AUD$400,000.
Pharmaxis earns regulatory thumbs-up for Aridol
13 February, 2006 by Helen SchullerThe Australian Drug Evaluation Committee has recommended to the TGA that Sydney-based drug developer Pharmaxis' (ASX:PXS) first product, the asthma diagnostic and treatment management tool Aridol, be registered for sale in Australia.
Analytica chairman defends cash position
13 February, 2006 by Ruth BeranThe ASX has issued a 'please explain' to Brisbane-based Analytica (ASX:ALT), querying whether the company will have enough cash to last it past the next quarter.
Stirling study shows reduced weight gain in rats
09 February, 2006 by Ruth BeranA study conducted for Perth-based Stirling Products (ASX:STI) has shown that its beta agonist ST810 reduced weight gain in obese Zucker rats.
Alchemia's synthetic heparin completes pilot scale process
09 February, 2006 by Ruth BeranThe first batch of Brisbane biopharma Alchemia's (ASX:ACL) synthetic heparin has completed purification -- the final stage of the pilot scale process development -- at the US facilities of the company's manufacturing partner, The Dow Chemical Company.
Ventracor implants 50, reaches CE Mark trial enrolment target
09 February, 2006 by Helen SchullerArtificial heart company Ventracor (ASX: VCR) has implanted its 50th VentrAssist left ventricular assist device (LVAD) and has reached the enrolment target of 30 implants in its European CE Mark trial.
